ERBB2 and breast cancer: Another study analyzed the cardiovascular safety of continuing trastuzumab in combination with lapatinib in stage IV HER-2+ BC patients whose disease progressed during trastuzumab treatment and showed that the incidence of asymptomatic LVEF decline and congestive heart failure was lower in the combination group (2 and 3.4%, respectively) than in the lapatinib-only group (0.7 and 1.4%, respectively) (62).